Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

News provided by

Oct 02, 2018, 08:00 ET

SAN FRANCISCO, Oct. 2, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held from November 7 to November 11, 2018, at the Walter E. Washington Convention Center in Washington, D.C.

In addition to the ten data abstracts, Deborah Charych, Ph.D., Executive Director, Research Biology, Nektar Therapeutics will give an invited presentation "Harnessing Potent Immune Agonist Pathways through Kinetic Engineering," which will be featured during the Cytokines Reinvented Session on November 9, 2018.

"We are excited that ten separate abstracts with Nektar pipeline molecules have been accepted for presentation at this year's SITC meeting," said Jonathan Zalevsky, Ph.D., Senior Vice President and Chief Scientific Officer at Nektar. "These abstracts showcase the progress we've made across our portfolio ranging from clinical and preclinical stage programs and spanning both large molecule and small molecule modalities. The data presented will also demonstrate the progress we've made across our portfolio characterizing how these unique mechanisms can be used to target and activate multiple elements of the immune system. These preclinical and clinical data reinforce the potential of our therapies to serve as foundational therapies in immuno-oncology."

Oral Presentation:

Abstract Title: "Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma"
Abstract: #O4
Presenter: Dr. Adi Diab, MD Anderson Cancer Center
Session Title: Cytokines Reinvented
Date: Friday, November 9, 2018, 5:05 p.m. – 6:30 p.m. Eastern Standard Time

Poster Presentations:

Combination Therapy

Abstract #P364: "Systemic anti-tumor immunity and immune memory formation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214", Kivimae, S., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10^th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Abstract #P378: "NKTR-214 (CD122-biased agonist) and NKTR-262 (TLR7/8 agonist) combination treatment pairs local innate immune activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity", Rolig, A., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10^th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Abstract #P368: "Combination of a Dipeptidyl Peptidase Inhibitor BXCL701 and Biased CD122 Agonist NKTR-214 with Anti-PD1 Provides Functional Immunological Memory through Inflammatory Cell Death", MacDougall, J., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Abstract #P348: "Survival and immune modulation in homologous recombination deficient murine ovarian tumors using the PARP inhibitor, rucaparib and immune agonist, NKTR-214", Charych, D., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10^th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Cytokines in Anti-Tumor Immunity

Abstract #P418: "Pre-clinical investigation of NKTR-255, a polymer-conjugated IL-15 with a potent NK cell dependent anti-tumor efficacy", Miyazaki, T., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10^th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Abstract #P419: "NKTR-214 in combination with radiation produces a potent in situ vaccine in the syngeneic B78 melanoma model", Sondel, P., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10^th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Abstract #P422: "A polymer-associated human IL-15 (NKTR-255) has optimized biological activity and unique mechanisms of action on CD8 T Cells and NK Cells", Robinson T., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10^th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Abstract #P424: "NKTR-214, an engineered IL-2, selectively depletes intratumoral Tregs and expands immunotherapy-induced effector T cell responses", Sharma, M., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10^th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Mechanisms of Resistance to Immunotherapy

Abstract #P557: "Overcoming genetically-based resistance mechanisms to PD-1 blockade", Torrejon, D., et al.
Session Date and Time: Friday, November 9^th from 8 a.m. – 8 p.m. and Saturday, November 10^th from 8 a.m. – 8:30 p.m. Eastern Standard Time

Company to Host Webcast Conference Call at SITC
The company will host a webcast conference call with melanoma specialists and company management on Saturday, November 10^th at 9:30 a.m. Eastern time during the SITC conference following presentation of data. The webcast conference call will be accessible from the Investor Events page of Nektar's website at http://ir.nektar.com/events-and-presentations/events.

About Nektar
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be identified by words such as: "will," "believe," "can," "serve" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the therapeutic potential of our pipeline molecules alone or in combination with other therapeutic agents, and the availability of results and outcomes from clinical and preclinical studies of our new drug candidates. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of our pipeline molecules are based on preclinical and clinical findings and observations; (ii) NKTR-214 and most of our pipeline molecules are in early stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied prior to regulatory approval due to lack of sufficient efficacy, safety considerations or other factors that impact drug development; (iii) data reported from ongoing preclinical and clinical trials are necessarily interim data only and the final results will change based on continuing observations; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of potential new drug candidates (such as NKTR-214, NKTR-262 and NKTR-255) is therefore very uncertain and unpredictable; (v) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vi) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2018. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

For Investors:

Jennifer Ruddock of Nektar Therapeutics
415-482-5585

Jodi Sievers of Nektar Therapeutics
415-482-5593

For Media:

Dan Budwick of 1AB
973-271-6085
[email protected]

SOURCE Nektar Therapeutics